47 min listen
Episode 1: Surrogate Endpoints in AML
ratings:
Length:
26 minutes
Released:
Mar 11, 2022
Format:
Podcast episode
Description
Bernie Marini and Anthony Perissinotti discuss the following paper on whether or not event-free survival (EFS) is an appropriate surrogate endpoint for overall survival (OS) in AML:
Norsworthy KJ, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. J Clin Oncol. 2022 Mar 10;40(8):847-854. PMID: 34890212.
Norsworthy KJ, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. J Clin Oncol. 2022 Mar 10;40(8):847-854. PMID: 34890212.
Released:
Mar 11, 2022
Format:
Podcast episode
Titles in the series (25)
Episode 3.1: History of Acute Lymphoblastic Leukemia Treatment and Building the BFM Backbone by WolverHeme Happy Hour